We’re excited to announce that on Tuesday, April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (pronounced jin-AR-kew and also known as tolvaptan) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common form of polycystic kidney disease (PKD).
My name is Joy Pekar and I am one of the Hamilton Chapter Coordinators. Both my husband and his mother have PKD, and I first became involved with the PKD Foundation of Canada as a way to learn more about this disease. As my husband's illness progressed, I was grateful for the resources that the Foundation provided, and as I watched his kidney fail, I became even more motivated to raise funds to support research in the hopes that one day no one will experience the detrimental effects of this disease. I love that the PKD Foundation of Canada create a circle of support where members can learn from each other's experiences and support each other through their journeys.
I hope you can join us for our next meeting or event!
Kidney Month is recognized in March across Canada and the United States. We spend this time raising awareness of the importance of our kidneys to our overall health, and to reduce the frequency and impact kidney disease and its associated health problems have on an international level. We encourage you all to get out there and share your PKD journey with as many people as possible!
Submitted by Chiara Gamberi, Ph. D.
Affiliate Assistant Professor, Department of Biology, Concordia University
We are pleased to share some encouraging news regarding the treatment landscape for those living with ADPKD. Today, Otsuka announced results from their Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). This data was presented at the American Society of Nephrology (ASN) Conference in New Orleans and published online in the New England Journal of Medicine.
We are glad to share some great news for the Canadian PKD community, as tolvaptan receives positive results from an additional one year international trial. The trial outcome was positive for tolvaptan in the treatment of ADPKD. Also of note, the trial had participation from Canadian patients and nephrologists.
Posted by Vilija Batten · November 29, 2019 9:03 AM
Posted by Suita Beck · November 21, 2019 2:37 PM
Posted by Suita Beck · November 05, 2019 9:32 AM